UC-GENOME is a real-world cohort of patients with metastatic urothelial carcinoma (UC). The study consisted of two co-equal aims: 1) to provide targeted DNA sequencing for clinical decision making at no cost to patients; and 2) to create a resource for collaborative translational science including a clinically annotated biobank. The submitted data represents the foundational analysis of 218 patients accrued at 7 academic medical centers. The analysis includes 176 patients with both targeted DNA sequencing and RNA sequencing. The genomic data was combined with clinical variables to model response to chemotherapy and immune checkpoint inhibitors (ICI). Due to additional sharing restrictions, data from one site can be found in <a href="https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003094">phs003094</a>.

Urothelial Cancer - Genomic Analysis to Improve Patient Outcomes and    Research (UC-GENOME): A Bladder Cancer Advocacy Network (BCAN)-Led    Collaborative Research Pilot Study

13 variables across Demographics, Disease Events

Variables — phs003066 — Urothelial Cancer - Genomic Analysis to Improve Patient Outcomes and    Research (UC-GENOME): A Bladder Cancer Advocacy Network (BCAN)-Led    Collaborative Research Pilot Study

Urothelial Cancer - Genomic Analysis to Improve Patient Outcomes and Research (UC-GENOME): A Bladder Cancer Advocacy Network (BCAN)-Led Collaborative Research Pilot Study

Demographics (2)

Disease Events (1)

Other (10)